OSLO, Nov. 16, 2018 /PRNewswire/ -- Targovax ASA TRVX, a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces that CMO Magnus Jäderberg will present at the NeoAg Summit 2018 (formerly Neoantigen Summit) in Boston
NeoAg Summit 2018
Date: 16 November 2018
Presenter: Dr. Magnus Jäderberg, CMO
Presentation time: 11:00 ET
Venue: Hyatt Regency Cambridge, Boston.
Title: TG01, a neo-antigen specific vaccine targeting RAS mutations in solid tumours
Presentation slides will be available on www.targovax.com/Investors.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47-922-61-624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47-9300-1773
Email: andreas.tinglum@corpcom.no
Simon Conway/Stephanie Cuthbert - FTI Consulting (International)
Phone: +44-20-3727-1000
Email: Targovax@fticonsulting.com
This information was brought to you by Cision http://news.cision.com
http://news.cision.com/targovax/r/targovax-to-present-at-neoag-summit-2018,c2673975
SOURCE Targovax
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.